Capricor Therapeutics (CAPR) in Pivotal Point Check: FDA Breakthrough in Heart Muscle Therapy Sparks Stock Rally - Here's the Roadmap to Approval!
Reading Time: 4 minutes
FDA lifts halt on review: The U.S. health authority accepts the resubmission for the drug Deramiocel and sets a final decision date for August 22, 2026. No outstanding deficiencies: After reviewing the new Phase 3 data (HOPE-3), the agency has not reported any further objections for the time being. Market exclusivity in sight: With approval, Capricor expects to gain a valuable "Priority Review Voucher," which can expedite the development of other drugs or be sold for high sums. Capricor Therapeutics is a U.S. biotechnology...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
